🇺🇸 FDA
Pipeline program

ZW25 (Zanidatamab)

ZWI-ZW25-203

Phase 2 small_molecule completed

Quick answer

ZW25 (Zanidatamab) for HER2-amplified Biliary Tract Cancers is a Phase 2 program (small_molecule) at BeOne Medicines with 1 ClinicalTrials.gov record(s).

Program details

Company
BeOne Medicines
Indication
HER2-amplified Biliary Tract Cancers
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials